Weight regain after hormone treatment: possible link to low muscle mass and benefits of adding testosterone in men

GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, and triple GIP/GLP-1 receptor/glucagon agonists achieve 15% to 22% placebo-subtracted weight loss.

• Long-term effectiveness of these treatments may depend on the sustainability of weight loss and the composition of the weight lost.
• Weight loss from these medications may include a reduction in lean tissue, raising concerns about muscle mass loss compared to other weight-loss methods.
• Obesity in men is often linked to low testosterone levels, which may lead to decreased muscle mass, higher levels of fat around internal organs, worse insulin sensitivity, and heightened cardiovascular risk.

Simplified